CLVS Clovis Oncology, Inc.

7.760.75 (+10.7%)
Close: November 21, 2019

7.71-0.05 (-0.64%)
After hours

Quote

Previous Close
$7.76
Day Range
$7.00-$8.02
52 Week Range
$2.93-$32.05
Volume
8,137,880
Avg Volume
7,922,650
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$425.37M
Enterprise Value (EV)
$440.61M
PE Ratio
-
EV/EBITDA
-1.34
Price/Sales
4.03
Price/Book
2.90
PEG Ratio
1.78

Financials

Revenue
$95.39M
Gross Profit
$73.31M
EBITDA
-$329.21M
EPS, ttm
-$7.51
Profit Margin
-
Revenue/Employee
$203.82K
Next Earnings Date
2/25/2020 (95 days)
Debt to Equity
394%
Debt
$535.39M
Cash
$520.15M
Net Debt
$15.24M

Performance

Beta
1.50
200 Day Moving Avg
$13.78
50 Day Moving Avg
$4.35
52 Week Change
-59.92%
YTD Change
-53.15%
1 Month Change
103.78%
3 Month Change
15.68%
6 Month Change
-59.74%
1 Year Change
-59.92%
2 Year Change
-89.03%
5 Year Change
-86.20%

Share Count

Shares Outstanding
54.8M
Float
52.3M
Restricted Shares
2.5M
Restricted Shares, %
4.53%

Clovis Oncology, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Patrick J. Mahaffy

Website: http://www.clovisoncology.com

Description: Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Employees: 468